PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS...

Value in Health 2019 / 11 Vol. 22

PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA

Avxentyev, N.A., Frolov, M., Makarov, A., Palencia, R., Kudelya, O.V., Kovaleva, E.R.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.578
Date:
November, 2019
File:
PDF, 381 KB
2019
Conversion to is in progress
Conversion to is failed